Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
17-Feb-2025 | 999 | 1,000 | 945.3 | 960 | 25,961 | 16,73,12,143.05 | 90,855 |
18-Feb-2025 | 971 | 1,018 | 941.5 | 985.55 | 31,519 | 36,07,22,671.4 | 99,736 |
19-Feb-2025 | 985 | 1,014.9 | 970 | 996.05 | 15,129 | 11,61,31,347.95 | 80,501 |
20-Feb-2025 | 996.05 | 1,021.9 | 985.8 | 992 | 13,719 | 13,92,59,359.2 | 1,02,974 |
21-Feb-2025 | 992 | 1,009.3 | 980 | 995.75 | 7,733 | 8,92,02,297.8 | 53,903 |
24-Feb-2025 | 980 | 1,004.7 | 973.5 | 979.85 | 10,728 | 17,19,22,205.15 | 1,30,339 |
25-Feb-2025 | 979 | 1,012.1 | 975 | 987.7 | 6,934 | 8,97,85,015.1 | 49,214 |
27-Feb-2025 | 988 | 993.2 | 966.95 | 976.6 | 11,850 | 9,28,35,942 | 61,200 |
28-Feb-2025 | 966.95 | 999.65 | 960.05 | 981.7 | 5,559 | 9,14,18,396.65 | 61,036 |
03-Mar-2025 | 979.4 | 979.4 | 935.25 | 956.5 | 9,358 | 6,93,78,186.65 | 42,279 |
04-Mar-2025 | 954.55 | 968.7 | 936 | 946.1 | 4,916 | 6,47,30,220.85 | 39,057 |
05-Mar-2025 | 946.1 | 977.75 | 940.75 | 965.5 | 5,313 | 6,13,31,085.55 | 41,687 |
06-Mar-2025 | 979.4 | 999 | 971.3 | 980 | 3,807 | 4,49,84,256.5 | 18,626 |
07-Mar-2025 | 986.45 | 997.45 | 969 | 970.6 | 4,540 | 4,36,20,366.95 | 26,358 |
10-Mar-2025 | 970.6 | 977 | 935 | 940.2 | 7,741 | 11,03,57,875.8 | 96,991 |
11-Mar-2025 | 944 | 962.1 | 936 | 945.5 | 8,712 | 5,50,04,698.45 | 23,930 |
12-Mar-2025 | 954 | 954 | 922 | 925.55 | 4,797 | 3,74,95,482.4 | 27,465 |
13-Mar-2025 | 931 | 944.05 | 916.75 | 927.7 | 6,078 | 7,66,54,812.3 | 51,344 |
17-Mar-2025 | 934 | 939.75 | 910.95 | 925.55 | 7,677 | 15,01,03,945.6 | 1,18,297 |
EBITDA margin slightly declined, down 80 basis points to 20.8% in Q2, reflecting some operational pressures.
The allotment of shares was finalised on July 8, and Emcure Pharma shares were scheduled to be listed on the BSE and NSE on July 10.
The IPO comprised a mix of fresh equity sale and an offer for sale (OFS).
The categories earmarked for NII and QIB investors received the most subscriptions, at 47.98 and 193.06 times, respectively.
The IPO is priced between Rs 960 and Rs 1008 a share, with buyers able to bid for 14 shares per lot.
According to BSE data, the initial share sale attracted bids for 1,80,40,960 shares, with 1,37,03,538 shares on offer.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
